- •We report a central review for resectability of 448 patients with metastatic colorectal cancer receiving first-line therapy (FIRE-3 trial).
- •Twenty-two percent of the patients before systemic therapy and 53% of the patients at best response were considered candidates for resection.
- •Actual reported resectability was 16% in the evaluated cohort.
- •Actual resection rates were significantly associated with treatment context (university hospital versus other hospitals/practices).
Patients and methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Clinical practice guidelines in oncology (NCCN Guidelines®) colon cancer version 2.2016.2016
- Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.HPB (Oxford). 2013; 15: 119-130
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann Oncol. 2016; 27: 1386-1422
- Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Ann Surg. 2004; 240 (discussion 657–648): 644-657
- Is survival for patients with resectable lung metastatic colorectal cancer comparable to those with resectable liver disease? Results from the South Australian Metastatic Colorectal Registry.Ann Surg Oncol. 2016; 23: 3616-3622
- Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis.ISRN Oncol. 2011; 2011763245
- Improving resectability of hepatic colorectal metastases: expert consensus statement.Ann Surg Oncol. 2006; 13: 1271-1280
- Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease.Lancet Oncol. 2009; 10: 801-809
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.Lancet Oncol. 2013; 14: 1208-1215
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.Lancet Oncol. 2010; 11: 38-47
- FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: a phase II randomized study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.J Clin Oncol. 2016; 34 (suppl; abstr 3512)
- Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.N Engl J Med. 2014; 371: 1609-1618
- CALGB/SWOG 80405: analysis of patients undergoing surgery as part of treatment strategy.Ann Oncol. 2014; 25 (abstr LBA10): v1-v4
- Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial.JAMA. 2017; 317: 2392-2401
- PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.J Clin Oncol. 2014; 32: 2240-2247
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.Lancet Oncol. 2014; 15: 1065-1075
- Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer.J Clin Oncol. 2015; 33: 3718-3726
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.Lancet Oncol. 2016; 17: 1426-1434
- Measures of response agreement for qualitative data: some generalizations and alternatives.Psychol Bull. 1971; 76: 365-377
- Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer.Ann Surg Oncol. 2016; 23: 375-381
- R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?.Ann Surg. 2008; 248: 626-637
- Selecting patients for a second hepatectomy for colorectal metastases: an systemic review and meta-analysis.Eur J Surg Oncol. 2014; 40: 1036-1048
- Selection for hepatic resection of colorectal liver metastases: expert consensus statement.HPB (Oxford). 2013; 15: 91-103
- Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.Ann Surg. 2006; 243: 1-7